NBIP-'2118 / Neurocrine - LARVOL DELTA

Details of Neurocrine's transformed R&D engine, designed to deliver at least four new Phase 1 and two Phase 2 programs per year by focusing on genetically or clinically validated mechanisms of action were shared during today's event. Highlighted programs include: (PRNewswire) - "NBI-'569, a dual M1 / M4 agonist for Alzheimer's psychosis, and NBI-'567, an M1 preferring agonist for Alzheimer's cognition and Lewy body dementia; Next-generation VMAT2 inhibitors; NBI-'890 and NBI-'675, engineered for increased half-life and potency and decreased solubility, and which provide the potential for long-acting injectable administration across multiple central nervous system indications; A suite of differentiated assets for better quality weight loss, including NBIP-'2118, a CRF2 agonist expected to enter Phase 1 development in the first half of 2026....Neurocrine plans to provide update on its emerging early-stage Neurology and Immunology pipeline in 2026."

New P1 trial • Pipeline update • Alzheimer's Disease • Dementia • Lewy Body Disease • Obesity